COVID-19 Resources
COVID-19 vaccination in patients with solid tumours - Position Statement
This position statement has been developed for cancer clinicians and other healthcare professionals caring for people with cancer. The COVID-19 pandemic is constantly evolving and the position statement may be updated with emergence of new evidence.
Links to available guidance to support clinical decision-making about cancer management for cancer patients with COVID-19
Links to available international guidance regarding considerations for cancer management for cancer patients with COVID-19 are provided below. This may include cancer patients with both symptomatic and asymptomatic SARS-CoV-2 infection.
PBAC Recommendation for molnupiravir (Lagevrio®)Item
25 February 2022
The Pharmaceutical Benefits Advisory Committee (PBAC) undertook an expedited consideration of a sponsor submission to add molnupiravir (Lagevrio®) to the Pharmaceutical Benefits Scheme (PBS) for use in treating patients with mild to moderate COVID-19 who are at risk of developing severe disease requiring hospitalisation. The expedited consideration by PBAC recognises the urgent public health need related to the prevention, management, or treatment of SARS-CoV-2 infections. The PBAC recommended the listing on the PBS of molnupiravir as a General Schedule, Authority Required (Streamlined) benefit. The outcome of the PBAC consideration is available on the PBS website.
New COVID-19 oral antiviral treatment, LAGEVRIO (molnupiravir) granted Therapeutic Goods Administration (TGA) provisional approval of MSD’s COVID-19 oral for treatment of adults with COVID-19
20 January 2022
Molnupiravir has provisional approval for the treatment of adults with COVID- 19 who do not require initiation of oxygen due to COVID and who are at increased risk of progression to severe COVID-19, including hospitalisation or death.
The decision to approve this indication was based on the analysis of efficacy and safety data from a Phase 3 trial. Continued approval of this indication depends on additional data.
Molnupiravir is an orally administered antiviral treatment that inhibits the replication of SARS-CoV-2, the causative agent of COVID-19. Molnupiravir has been investigated for the treatment of non- hospitalised adults, with mild-to-moderate laboratory-confirmed COVID-19, with at least one risk factor for severe illness.
1 Bernal AJ, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients | NEJM N Engl J Med DOI: 10.1056/NEJMoa2116044. 16 Dec 2021.
Cancer Australia’s Frequently Asked Questions (FAQs) about COVID-19 vaccines for people affected by cancer is regularly updated based on information and evidence currently available in Australia and internationally
This is a valuable resource for patients
Information and answers to FAQs about COVID-19 vaccines for Aboriginal and Torres Strait Islander people affected by cancer
FAQs have been translated into the ten most commonly spoken languages in Australia other than English: available at www.canceraustralia.gov.au/CALD.
Information provided by the Australian Government for clinicians and the Australian community about COVID-19 vaccines in Australia